Iconic #heartfailure trialist @FaiezZANNAD presents meta-analysis of EMPEROR-Reduced and DAPA-HF trials #CVCT2020 @FaiezZANNAD @drdargaray @lucreciamburgos @ersied727 @CVCTForum @SantosGallegoMD @rachkataria @AlexNowbar @vbluml @KevinShahMD @paomorejon
Beneficial effects irrespective of diabetes status, use of ARNI or baseline renal function
Benefits seen across spectrum of age, gender, BMI, history of #heartfailure
Greater benefits seen in
NYHA Class 2 patients
Asian and Africa-Caribbean ethnicity
Intriguing fining of lower benefits seen in Europe compared to Americas or Asia (?chance effect)
Conclusion slide by @FaiezZANNAD talk on Meta-analysis of SGLT2I (Dapagliflozin and Empagliflozin) in HFrEF
Read on Twitter
in primary outcome of 1st HHF/CV death